摘要
目的:观察阿德福韦酯(adefovir dipivoxil)联合胸腺肽α1(thymosin α1)治疗慢性乙型肝炎的疗效。方法:102例慢性乙型肝炎患者随机分为2组,治疗组51例,应用胸腺肽α11.6mg,每周2次,皮下注射,持续6个月,同时口服阿德福韦酯10mg,qd,疗程12个月;对照组51例,单用阿德福韦酯,用量、用法及疗程与治疗组相同。观察治疗前、后临床症状、肝功能、乙肝病毒标志物及乙肝病毒复制指标。结果:在ALT复常率及HBVDNA下降水平情况等方面,在治疗6个月时,治疗组与对照组相比,P<0.05,在疗程结束时,2组相比,差异无显著性;在HBVDNA阴转及HBeAg血清转换方面,2组相比,P>0.05;在临床疗效方面,治疗组与对照组有效率分别为88%,80%,但差异无统计学意义。结论:阿德福韦酯、胸腺肽α1两药联合治疗慢性乙型肝炎,具有明显的协同作用,能较快地抑制病毒复制、减轻肝脏炎症,改善肝功能及临床症状。
OBJECTIVE To observe the treatment effect of adefovir dipivixil in combination with thymosin al on chronic hepatitis B. METHODS The 102 patients with chronic hepatitis B were divided into two groups randomly. The treated group of 51 patients was treated by subcutaneous injection of thymosin α1 1.6 mg twice per week for 6 months in combination with taking adefovir dipivixil 10 mg per day for 12 months while the controlled group was treated with single adefovir dipivixil with same dose and therapy methods and period of treatment. The aim of this study was to measure the symptom, liver function, hepatitis B virus marker and viral replication indexes in hepatitis B before and after treatment. RESULTS At week 6, on ALT normalization and on removing HBV DNA, the treated group was compared with the controlled group P〈0. 05. At end of treatment, there was no significant difference. On HBVDNA negative changing rate and HBeAg seroconversion, after comparison, P〉0. 05; On clinical treatment effect, the curing rate of the treated group and the controlled group were 88% and 80% respectively, with no significant difference. CONCLUSION The combination treatment of adefovir dipivixil and thymosin α1 is effective on chronic hepatitis B by inhibiting virus replication rapidly, relieving liver inflammation,improving liver function and clinical symptom.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2008年第23期2022-2024,共3页
Chinese Journal of Hospital Pharmacy
